Our KISIMA™ cancer vaccine (ATP-128)* is a modular, self-adjuvanting peptide-based cancer vaccine that carries a multi-antigenic cargo, which has the potential to strengthen the capability of the patient’s immune system to recognize and kill tumor cells.1
Clinical trials (monotherapy and combination therapy): Our KISIMA™ cancer vaccine (ATP-128) is being investigated as a monotherapy and in combination with ezabenlimab* (BI 754091), a programmed death-1 (PD-1) inhibitor, in patients with advanced colorectal cancer (CRC).2
This cancer vaccine is based on the KISIMATM technology platform
Our cancer vaccine is a therapeutic chimeric recombinant protein vaccine that is based on the KISIMATM technology platform.1 The KISIMATM platform is engineered to induce an efficient immune response via activation of helper and cytotoxic T cells, and to promote immunologic memory.3
In order to induce a potent tumor-specific immune response, a therapeutic vaccine needs to stimulate multi-epitopic CD8+ cytotoxic T lymphocyte-mediated immunity, induce CD4+ helper T cells and promote immunologic memory.4 Our KISIMA™ cancer vaccine (ATP-128) therefore includes three components in a single fusion protein, which is then used as a vaccine: first, a cell-penetrating peptide for antigen delivery; second, a multi-antigenic cargo that is tailored to raise an immune response against colorectal tumors; and third, a toll-like receptor (TLR) peptide agonist as an adjuvant.3
Mechanism of action
The KISIMA™ cancer vaccine (ATP-128) is engineered to induce an efficient immune response and promote immunologic memory via the activation of cytotoxic T cells and helper T cells.1,4,5
Preclinical evidence supports the safety and immunogenicity of a previous generation of the KISIMA™ cancer vaccine in an in vivo model of CRC.3 This cancer vaccine has been shown to induce highly potent helper and cytotoxic T-cell responses in several murine tumor models.3 The cell-penetrating peptide and the TLR agonist components of the vaccine platform have been shown to act together to elicit both CD8+ and CD4+ antigen-specific T-cell immune responses in vivo.3
This previous generation of the cancer vaccine also resulted in favorable changes in the tumor microenvironment, including tumor infiltration of antigen-specific effector T cells, reduction of myeloid-derived suppressor cells and regulatory T cells, and M1 polarization of macrophages.3
Combination with PD-1 blockade has been shown to have an additive effect and to significantly increase the efficacy of the KISIMA™ cancer vaccine (ATP-128) in vivo.5 T-cell infiltration is enhanced, which could sensitize PD-1-resistant tumors (which have been shown to have limited immune infiltration) to checkpoint inhibitors.3
Our KISIMA™ cancer vaccine (ATP-128) is currently being investigated as a monotherapy and in combination with ezabenlimab (BI 754091) in patients with Stage IV CRC.2
|Trial number||Phase||Treatment||Patient population||Status|
KISIMA™ cancer vaccine (ATP-128) (monotherapy and in combination with ezabenlimab [BI 754091])
Histologically or cytologically confirmed Stage IV CRC
Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/press-release/acquisition-amal-therapeutics (Accessed: February 2021).
ClinicalTrials.gov. NCT04046445. https://clinicaltrials.gov/ct2/show/NCT04046445 (Accessed: February 2021).
Belnoue E, et al. JCI Insight 2019;4(11):e127305.
AMAL Therapeutics. Therapeutic Vaccines. http://amaltherapeutics.com/science/therapeutic-vaccines/ (Accessed: March 2020).
Boehringer Ingelheim. Data on file.
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2021 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: March 2021
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue